Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

 Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

Bayer Reports Results of Xarelto (rivaroxaban) in P-III EINSTEIN-Jr. Study for Venous Thromboembolism

Shots:

  • The P-III EINSTEIN-Jr. study involves assessing of Xarelto (20mg) vs SOC (heparins as monothx. or in combination with Vit.K antagonist like warfarin) in 500 children in ratio (2:1) with acute VTE who had started heparin therapy aged ≤ 17yrs.
  • The P-III EINSTEIN-Jr. study results: VTE reoccurrence (1.2% vs 3.0%); improvement in thrombotic burden; bleeding episode [3% (all non-major bleeds) vs 1.9% (2 major & 1 non-major)]; safety profile is consistent to prior studies in adults
  • Xarelto is a non-vitamin K antagonist oral anticoagulant (NOAC) and is approved for eight indications, jointly developed by Bayer & Janssen. Bayer plans to submit MAA to EMA for extension of the Xarelto, making it available for children with VTE

Click here to read full press release/ article | Ref: Bayer | Image: Yahoo Finance

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post